Roles of p38α mitogen-activated protein kinase in mouse models of inflammatory diseases and cancer

FEBS Journal

Volumn 282, Issue 10, 2015, Pages 1841-1857

  Gupta, Jalaj ^a,c   Nebreda, Angel R ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

cancer; inflammation; mouse models; p38 MAPK; signaling pathways; therapy; tumor initiation; tumor promotion

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 17; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BREAST CANCER; CANCER INHIBITION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COLON CANCER; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; EXPERIMENTAL ANIMAL; HUMAN; IN VIVO STUDY; INFLAMMATORY DISEASE; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN CANCER; ANIMAL; ENZYMOLOGY; GENETICS; INFLAMMATION; METABOLISM; NEOPLASM; PHYSIOLOGY;

MUS;

ANIMALS; HUMANS; INFLAMMATION; NEOPLASMS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84929571913     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13250     Document Type: Article

References (119)

1. Freshney NW, Rawlinson L, Guesdon F, Jones E, Cowley S, Hsuan J, &, Saklatvala J, (1994) Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 78, 1039-1049.
2. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al,. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
3. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, &, Nebreda AR, (1994) A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 78, 1027-1037.
4. Han J, Lee JD, Bibbs L, &, Ulevitch RJ, (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811.
5. Trempolec N, Dave-Coll N, &, Nebreda AR, (2013) SnapShot: p38 MAPK substrates. Cell 152, 924-924.e1.
6. Trempolec N, Dave-Coll N, &, Nebreda AR, (2013) SnapShot: p38 MAPK signaling. Cell 152, 656-656.e1.
7. Cuenda A, &, Rousseau S, (2007) p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773, 1358-1375.
8. Cuadrado A, &, Nebreda AR, (2010) Mechanisms and functions of p38 MAPK signalling. Biochem J 429, 403-417.
9. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S, Valladares A, Perez L, Klein R, &, Nebreda AR, (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6, 109-116.
10. Mudgett JS, Ding J, Guh-Siesel L, Chartrain NA, Yang L, Gopal S, &, Shen MM, (2000) Essential role for p38alpha mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 97, 10454-10459.
11. Beardmore VA, Hinton HJ, Eftychi C, Apostolaki M, Armaka M, Darragh J, McIlrath J, Carr JM, Armit LJ, Clacher C, et al,. (2005) Generation and characterization of p38beta (MAPK11) gene-targeted mice. Mol Cell Biol 25, 10454-10464.
12. Sabio G, Arthur JS, Kuma Y, Peggie M, Carr J, Murray-Tait V, Centeno F, Goedert M, Morrice NA, &, Cuenda A, (2005) p38gamma regulates the localisation of SAP97 in the cytoskeleton by modulating its interaction with GKAP. EMBO J 24, 1134-1145.
13. Brancho D, Tanaka N, Jaeschke A, Ventura JJ, Kelkar N, Tanaka Y, Kyuuma M, Takeshita T, Flavell RA, &, Davis RJ, (2003) Mechanism of p38 MAP kinase activation in vivo. Genes Dev 17, 1969-1978.
14. del Barco Barrantes I, Coya JM, Maina F, Arthur JS, &, Nebreda AR, (2011) Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development. Proc Natl Acad Sci USA 108, 12764-12769.
15. Han J, &, Sun P, (2007) The pathways to tumor suppression via route p38. Trends Biochem Sci 32, 364-371.
16. Wagner EF, &, Nebreda AR, (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9, 537-549.
17. Kotlyarov A, Neininger A, Schubert C, Eckert R, Birchmeier C, Volk HD, &, Gaestel M, (1999) MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1, 94-97.
18. Ronkina N, Kotlyarov A, Dittrich-Breiholz O, Kracht M, Hitti E, Milarski K, Askew R, Marusic S, Lin LL, Gaestel M, et al,. (2007) The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 27, 170-181.
19. Kang YJ, Chen J, Otsuka M, Mols J, Ren S, Wang Y, &, Han J, (2008) Macrophage deletion of p38alpha partially impairs lipopolysaccharide-induced cellular activation. J Immunol 180, 5075-5082.
20. Kim C, Sano Y, Todorova K, Carlson BA, Arpa L, Celada A, Lawrence T, Otsu K, Brissette JL, Arthur JS, et al,. (2008) The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9, 1019-1027.
21. Otsuka M, Kang YJ, Ren J, Jiang H, Wang Y, Omata M, &, Han J, (2010) Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 138, 1255-1265.
22. O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, Chen SL, Lowitz K, Rasa C, Visco D, et al,. (2007) Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. J Biol Chem 282, 34663-34671.
23. Risco A, del Fresno C, Mambol A, Alsina-Beauchamp D, MacKenzie KF, Yang HT, Barber DF, Morcelle C, Arthur JS, Ley SC, et al,. (2012) p38gamma and p38delta kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation. Proc Natl Acad Sci USA 109, 11200-11205.
24. Chabaud-Riou M, &, Firestein GS, (2004) Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis. Am J Pathol 164, 177-184.
25. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, &, Steiner G, (2000) Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43, 2501-2512.
26. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, et al,. (2006) A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 318, 132-141.
27. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, Rooseboom M, Kreutzer H, Cavalcanti F, Boots AM, et al,. (2008) A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFalpha. Br J Pharmacol 154, 153-164.
28. Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, &, Telliez JB, (2006) MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 177, 1913-1917.
29. Inoue T, Boyle DL, Corr M, Hammaker D, Davis RJ, Flavell RA, &, Firestein GS, (2006) Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritis. Proc Natl Acad Sci USA 103, 5484-5489.
30. Yoshizawa T, Hammaker D, Boyle DL, Corr M, Flavell R, Davis R, Schett G, &, Firestein GS, (2009) Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 183, 1360-1367.
31. Mnich SJ, Blanner PM, Hu LG, Shaffer AF, Happa FA, O'Neil S, Ukairo O, Weiss D, Welsh E, Storer C, et al,. (2010) Critical role for apoptosis signal-regulating kinase 1 in the development of inflammatory K/BxN serum-induced arthritis. Int Immunopharmacol 10, 1170-1176.
32. Guma M, Hammaker D, Topolewski K, Corr M, Boyle DL, Karin M, &, Firestein GS, (2012) Antiinflammatory functions of p38 in mouse models of rheumatoid arthritis: advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum 64, 2887-2895.
33. Ananieva O, Darragh J, Johansen C, Carr JM, McIlrath J, Park JM, Wingate A, Monk CE, Toth R, Santos SG, et al,. (2008) The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 9, 1028-1036.
34. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, &, Caulfield JP, (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60, 335-344.
35. Damjanov N, Kauffman RS, &, Spencer-Green GT, (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60, 1232-1241.
36. Gaestel M, Kotlyarov A, &, Kracht M, (2009) Targeting innate immunity protein kinase signalling in inflammation. Nat Rev Drug Discov 8, 480-499.
37. Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, et al,. (2010) A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 333, 797-807.
38. Krementsov DN, Thornton TM, Teuscher C, &, Rincon M, (2013) The emerging role of p38 mitogen-activated protein kinase in multiple sclerosis and its models. Mol Cell Biol 33, 3728-3734.
39. Namiki K, Matsunaga H, Yoshioka K, Tanaka K, Murata K, Ishida J, Sakairi A, Kim J, Tokuhara N, Shibakawa N, et al,. (2012) Mechanism for p38alpha-mediated experimental autoimmune encephalomyelitis. J Biol Chem 287, 24228-24238.
40. Noubade R, Krementsov DN, Del Rio R, Thornton T, Nagaleekar V, Saligrama N, Spitzack A, Spach K, Sabio G, Davis RJ, et al,. (2011) Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 118, 3290-3300.
41. Guo X, Harada C, Namekata K, Matsuzawa A, Camps M, Ji H, Swinnen D, Jorand-Lebrun C, Muzerelle M, Vitte PA, et al,. (2010) Regulation of the severity of neuroinflammation and demyelination by TLR-ASK1-p38 pathway. EMBO Mol Med 2, 504-515.
42. Huang G, Wang Y, Vogel P, Kanneganti TD, Otsu K, &, Chi H, (2012) Signaling via the kinase p38alpha programs dendritic cells to drive TH17 differentiation and autoimmune inflammation. Nat Immunol 13, 152-161.
43. Tietz SM, Hofmann R, Thomas T, Tackenberg B, Gaestel M, &, Berghoff M, (2014) MK2 and Fas receptor contribute to the severity of CNS demyelination. PLoS One 9, e100363.
44. Jirmanova L, Giardino Torchia ML, Sarma ND, Mittelstadt PR, &, Ashwell JD, (2011) Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood 118, 3280-3289.
45. Jagavelu K, Tietge UJ, Gaestel M, Drexler H, Schieffer B, &, Bavendiek U, (2007) Systemic deficiency of the MAP kinase-activated protein kinase 2 reduces atherosclerosis in hypercholesterolemic mice. Circ Res 101, 1104-1112.
46. Tang-Feldman YJ, Lochhead SR, Lochhead GR, Yu C, George M, Villablanca AC, &, Pomeroy C, (2013) Murine cytomegalovirus (MCMV) infection upregulates P38 MAP kinase in aortas of Apo E KO mice: a molecular mechanism for MCMV-induced acceleration of atherosclerosis. J Cardiovasc Transl Res 6, 54-64.
47. Seimon TA, Wang Y, Han S, Senokuchi T, Schrijvers DM, Kuriakose G, Tall AR, &, Tabas IA, (2009) Macrophage deficiency of p38alpha MAPK promotes apoptosis and plaque necrosis in advanced atherosclerotic lesions in mice. J Clin Invest 119, 886-898.
48. McGuire VA, Gray A, Monk CE, Santos SG, Lee K, Aubareda A, Crowe J, Ronkina N, Schwermann J, Batty IH, et al,. (2013) Cross talk between the Akt and p38alpha pathways in macrophages downstream of Toll-like receptor signaling. Mol Cell Biol 33, 4152-4165.
49. -/- mice. PLoS One 6, e21055.
50. Dansky HM, Charlton SA, Sikes JL, Heath SC, Simantov R, Levin LF, Shu P, Moore KJ, Breslow JL, &, Smith JD, (1999) Genetic background determines the extent of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19, 1960-1968.
51. Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM, et al,. (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31, 62-69.
52. Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, &, Chung KF, (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63, 784-790.
53. Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, &, Higgins LS, (2008) p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation. J Pharmacol Exp Ther 324, 921-929.
54. Amano H, Murata K, Matsunaga H, Tanaka K, Yoshioka K, Kobayashi T, Ishida J, Fukamizu A, Sugiyama F, Sudo T, et al,. (2014) p38 Mitogen-activated protein kinase accelerates emphysema in mouse model of chronic obstructive pulmonary disease. J Recept Signal Transduct Res 34, 299-306.
55. Brando Lima AC, Machado AL, Simon P, Cavalcante MM, Rezende DC, Sperandio da Silva GM, Nascimento PG, Quintas LE, Cunha FQ, Barreiro EJ, et al,. (2011) Anti-inflammatory effects of LASSBio-998, a new drug candidate designed to be a p38 MAPK inhibitor, in an experimental model of acute lung inflammation. Pharmacol Rep 63, 1029-1039.
56. Duan W, Chan JH, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, &, Wong WS, (2005) Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 171, 571-578.
57. Liang L, Li F, Bao A, Zhang M, Chung KF, &, Zhou X, (2013) Activation of p38 mitogen-activated protein kinase in ovalbumin and ozone-induced mouse model of asthma. Respirology 18 (Suppl 3), 20-29.
58. Rincon M, &, Davis RJ, (2009) Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228, 212-224.
59. Arthur JS, &, Ley SC, (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 13, 679-692.
60. Alam MS, Gaida MM, Ogawa Y, Kolios AG, Lasitschka F, &, Ashwell JD, (2014) Counter-regulation of T cell effector function by differentially activated p38. J Exp Med 211, 1257-1270.
61. Lanna A, Henson SM, Escors D, &, Akbar AN, (2014) The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells. Nat Immunol 15, 965-972.
62. Mantovani A, Allavena P, Sica A, &, Balkwill F, (2008) Cancer-related inflammation. Nature 454, 436-444.
63. Hussain SP, &, Harris CC, (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121, 2373-2380.
64. Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, &, Paulos CM, (2014) Th17 cells in cancer: the ultimate identity crisis. Front Immunol 5, 276.
65. del Barco Barrantes I, &, Nebreda AR, (2012) Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 40, 79-84.
66. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, &, Wagner EF, (2007) p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39, 741-749.
67. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M, &, Nebreda AR, (2007) p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39, 750-758.
68. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, &, Fornace AJ Jr, (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 36, 343-350.
69. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, &, Bulavin DV, (2007) The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 26, 2502-2506.
70. Tront JS, Hoffman B, &, Liebermann DA, (2006) Gadd45a suppresses Ras-driven mammary tumorigenesis by activation of c-Jun NH2-terminal kinase and p38 stress signaling resulting in apoptosis and senescence. Cancer Res 66, 8448-8454.
71. Pereira L, Igea A, Canovas B, Dolado I, &, Nebreda AR, (2013) Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 5, 1759-1774.
72. Campbell RM, Anderson BD, Brooks NA, Brooks HB, Chan EM, De Dios A, Gilmour R, Graff JR, Jambrina E, Mader M, et al,. (2014) Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther 13, 364-374.
73. Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, &, Brown PH, (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69, 8853-8861.
74. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, &, Bacus SS, (2001) Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7, 171-177.
75. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, &, Bacus SS, (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100, 499-506.
76. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, &, Dowsett M, (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23, 2469-2476.
77. Salh B, Marotta A, Wagey R, Sayed M, &, Pelech S, (2002) Dysregulation of phosphatidylinositol 3-kinase and downstream effectors in human breast cancer. Int J Cancer 98, 148-154.
78. Wu X, Zhang W, Font-Burgada J, Palmer T, Hamil AS, Biswas SK, Poidinger M, Borcherding N, Xie Q, Ellies LG, et al,. (2014) Ubiquitin-conjugating enzyme Ubc13 controls breast cancer metastasis through a TAK1-p38 MAP kinase cascade. Proc Natl Acad Sci U S A 111, 13870-13875.
79. Ruiz EJ, Oeztuerk-Winder F, &, Ventura JJ, (2014) A paracrine network regulates the cross-talk between human lung stem cells and the stroma. Nat Commun 5, 3175.
80. Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, &, Yaffe MB, (2013) A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 5, 868-877.
81. Greenberg AK, Basu S, Hu J, Yie TA, Tchou-Wong KM, Rom WN, &, Lee TC, (2002) Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 26, 558-564.
82. Powell HA, Iyen-Omofoman B, Baldwin DR, Hubbard RB, &, Tata LJ, (2013) Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. J Thorac Oncol 8, 6-11.
83. El-Serag HB, &, Rudolph KL, (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557-2576.
84. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, &, Karin M, (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14, 156-165.
85. Sakurai T, Kudo M, Umemura A, He G, Elsharkawy AM, Seki E, &, Karin M, (2013) p38alpha inhibits liver fibrogenesis and consequent hepatocarcinogenesis by curtailing accumulation of reactive oxygen species. Cancer Res 73, 215-224.
86. Heinrichsdorff J, Luedde T, Perdiguero E, Nebreda AR, &, Pasparakis M, (2008) p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep 9, 1048-1054.
87. Iyoda K, Sasaki Y, Horimoto M, Toyama T, Yakushijin T, Sakakibara M, Takehara T, Fujimoto J, Hori M, Wands JR, et al,. (2003) Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 97, 3017-3026.
88. Yasuda E, Kumada T, Takai S, Ishisaki A, Noda T, Matsushima-Nishiwaki R, Yoshimi N, Kato K, Toyoda H, Kaneoka Y, et al,. (2005) Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma. Biochem Biophys Res Commun 337, 337-342.
89. Wang SN, Lee KT, Tsai CJ, Chen YJ, &, Yeh YT, (2012) Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 42, 1295-1301.
90. Gillen CD, Walmsley RS, Prior P, Andrews HA, &, Allan RN, (1994) Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35, 1590-1592.
91. Caballero-Franco C, Choo MK, Sano Y, Ritprajak P, Sakurai H, Otsu K, Mizoguchi A, &, Park JM, (2013) Tuning of protein kinase circuitry by p38alpha is vital for epithelial tissue homeostasis. J Biol Chem 288, 23788-23797.
92. Gupta J, Del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, &, Nebreda AR, (2014) Dual function of p38alpha MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival. Cancer Cell 25, 484-500.
93. Kang YJ, Otsuka M, van den Berg A, Hong L, Huang Z, Wu X, Zhang DW, Vallance BA, Tobias PS, &, Han J, (2010) Epithelial p38alpha controls immune cell recruitment in the colonic mucosa. PLoS Pathog 6, e1000934.
94. Wakeman D, Schneider JE, Liu J, Wandu WS, Erwin CR, Guo J, Stappenbeck TS, &, Warner BW, (2012) Deletion of p38-alpha mitogen-activated protein kinase within the intestinal epithelium promotes colon tumorigenesis. Surgery 152, 286-293.
95. Hayakawa Y, Hirata Y, Nakagawa H, Sakamoto K, Hikiba Y, Otsuka M, Ijichi H, Ikenoue T, Tateishi K, Akanuma M, et al,. (2010) Apoptosis signal-regulating kinase 1 regulates colitis and colitis-associated tumorigenesis by the innate immune responses. Gastroenterology 138, 1055-1067.
96. Chiacchiera F, Matrone A, Ferrari E, Ingravallo G, Lo Sasso G, Murzilli S, Petruzzelli M, Salvatore L, Moschetta A, &, Simone C, (2009) p38alpha blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1alpha- to FoxO-dependent transcription. Cell Death Differ 16, 1203-1214.
97. Chiacchiera F, Grossi V, Cappellari M, Peserico A, Simonatto M, Germani A, Russo S, Moyer MP, Resta N, Murzilli S, et al,. (2012) Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models. Cancer Lett 324, 98-108.
98. Urosevic J, Garcia-Albeniz X, Planet E, Real S, Cespedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, et al,. (2014) Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH. Nat Cell Biol 16, 685-694.
99. Docena G, Rovedatti L, Kruidenier L, Fanning A, Leakey NA, Knowles CH, Lee K, Shanahan F, Nally K, McLean PG, et al,. (2010) Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol 162, 108-115.
100. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, &, Schreiber S, (2002) p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J Immunol 168, 5342-5351.
101. Malamut G, Cabane C, Dubuquoy L, Malapel M, Derijard B, Gay J, Tamboli C, Colombel JF, &, Desreumaux P, (2006) No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. Dig Dis Sci 51, 1443-1453.
102. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, &, Van Deventer S, (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122, 7-14.
103. Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, et al,. (2006) Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4, 325-334.
104. Fan XJ, Wan XB, Fu XH, Wu PH, Chen DK, Wang PN, Jiang L, Wang DH, Chen ZT, Huang Y, et al,. (2014) Phosphorylated p38, a negative prognostic biomarker, complements TNM staging prognostication in colorectal cancer. Tumour Biol 35, 10487-10495.
105. Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ, &, Peppelenbosch MP, (2001) NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 20, 819-827.
106. Paillas S, Boissiere F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vie N, Marzi L, Cortijo C, et al,. (2011) Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. Cancer Res 71, 1041-1049.
107. Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, Xie C, Chen J, Deng Q, Yamout M, et al,. (2007) PRAK is essential for ras-induced senescence and tumor suppression. Cell 128, 295-308.
108. Yoshizuka N, Chen RM, Xu Z, Liao R, Hong L, Hu WY, Yu G, Han J, Chen L, &, Sun P, (2012) A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Mol Cell Biol 32, 606-618.
109. Cargnello M, &, Roux PP, (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75, 50-83.
110. Iriyama T, Takeda K, Nakamura H, Morimoto Y, Kuroiwa T, Mizukami J, Umeda T, Noguchi T, Naguro I, Nishitoh H, et al,. (2009) ASK1 and ASK2 differentially regulate the counteracting roles of apoptosis and inflammation in tumorigenesis. EMBO J 28, 843-853.
111. Hildesheim J, Bulavin DV, Anver MR, Alvord WG, Hollander MC, Vardanian L, &, Fornace AJ Jr, (2002) Gadd45a protects against UV irradiation-induced skin tumors, and promotes apoptosis and stress signaling via MAPK and p53. Cancer Res 62, 7305-7315.
112. Liu L, Rezvani HR, Back JH, Hosseini M, Tang X, Zhu Y, Mahfouf W, Raad H, Raji G, Athar M, et al,. (2014) Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generation. PLoS One 9, e97245.
113. Johansen C, Vestergaard C, Kragballe K, Kollias G, Gaestel M, &, Iversen L, (2009) MK2 regulates the early stages of skin tumor promotion. Carcinogenesis 30, 2100-2108.
114. Chang S, Iversen L, Kragballe K, Arthur JS, &, Johansen C, (2011) Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model. Cancer Investigat 29, 240-245.
115. Dickinson SE, Olson ER, Zhang J, Cooper SJ, Melton T, Criswell PJ, Casanova A, Dong Z, Hu C, Saboda K, et al,. (2011) p38 MAP kinase plays a functional role in UVB-induced mouse skin carcinogenesis. Mol Carcinog 50, 469-478.
116. Liu K, Yu D, Cho YY, Bode AM, Ma W, Yao K, Li S, Li J, Bowden GT, &, Dong Z, (2013) Sunlight UV-Induced skin cancer relies upon activation of the p38alpha signaling pathway. Cancer Res 73, 2181-2188.
117. Goldstein DM, Kuglstatter A, Lou Y, &, Soth MJ, (2010) Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 53, 2345-2353.
118. Del Reino P, Alsina-Beauchamp D, Escos A, Cerezo-Guisado MI, Risco A, Aparicio N, Zur R, Fernandez-Estevez M, Collantes E, Montans J, et al,. (2014) Pro-oncogenic role of alternative p38 mitogen-activated protein kinases p38gamma and p38delta, linking inflammation and cancer in colitis-associated colon cancer. Cancer Res 74, 6150-6160.
119. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, et al,. (2009) p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69, 4648-4655.